SMAD3 and breast carcinoma: As quantified by luciferase assay, non-malignant MCF10A breast cells and poorly-invasive MCF7 breast cancer cells treated with recombinant human TGF-β1 (rhTGF-β1) showed low TGF-β/SMAD3 signaling activity.